Oscotec

ACART studies therapy-adaptive cell states that enable a rare subset of cancer cells to survive treatment, repopulate, and contribute to acquired resistance.

SGA is a food material developed by Oscotec from natural plant components traditionally used in Korea as food.

Crystal Structure of Pim1 Kinase in Complex with a PyridoPyrimidine Derivative Suggests a Unique Binding Mode Human Pim1 kinase is a serine/threonine

Media: BioPharma APAC

Media: BioSpace

The page provides Oscotec’s latest official announcements and shareholder updates.

Oscotec offers career opportunities and invites applications via the provided form.

Oscotec collaborates to transform scientific innovation into therapeutic solutions.

The Board of Directors of Oscotec serves as the Company’s key decision-making body, reviewing and approving major management matters in accordance with the Board of Directors Regulations.

Oscotec is driven by experienced scientists, clinicians, and business leaders committed to transforming cancer treatment.

Oscotec shares its ESG activities, key policies, environmental, and social data.

Oscotec, a clinical-stage drug discovery and development company, focuses on advancing medicines while upholding ethics, responsibility, and transparency.

A Biotechnology Company Advancing Human Health

Oscotec respects the human rights of all stakeholders and operates a dedicated channel for raising concerns related to its business activities. All reports are handled promptly and fairly, ensuring strict confidentiality and protection from retaliation for anyone reporting in good faith.

Oscotec, a Korea-based biotech founded in 1998, discovers and develops medicines for oncology, immunology, neurodegeneration, and renal fibrosis.

OSCOTEC’s Articles of Incorporation establish the fundamental principles for transparent, responsible, and sustainable corporate governance.

Oscotec enhances management transparency and the reliability of its financial information through an independent audit body.

Oscotec conducts its business with integrity, fairness, and responsibility to build lasting trust with customers, shareholders, partners, employees, and local communities.

Oscotec secures two technology licensing agreements and restores profitability under its Value-Up corporate enhancement plan. The company exceeds its original timeline for these milestones, marking progress in its strategic initiatives. Licensing deals likely contribute to financial recovery and operational growth.

Nov 2026The Asia Business DailyNews article

OSCOTEC Inc. demonstrates a 600-fold return on investment after a 2.5 billion won investment generated 1.5 trillion won in loan origination (L/O) results through a new drug. The company attributes this success to its financial innovation in the corporate bond market. Credit spreads are analyzed as a key indicator of investor sentiment and capital flows, with OSCOTEC’s ‘Credit Signal’ tool offering insights into broader market trends.

Oct 2026edailyNews article

South Korean patients using **Leclaza** followed by **Rybrevant** (Johnson & Johnson) experience fewer early skin side effects while maintaining treatment efficacy. The study compares outcomes when Leclaza is administered first versus later in the regimen. Researchers confirm the combination retains its anticancer benefits despite reduced adverse reactions.

Oct 2026CHOSUNBIZNews article

BIT Computer partners with Amazon Web Services (AWS) to develop a large language model (LLM) tailored for the Korean healthcare sector. The collaboration aims to integrate advanced AI capabilities into healthcare applications and services. BIT Computer specializes in IT solutions for the healthcare industry.

Sep 2026Korea Biomedical ReviewNews article